LadRx Corp CYTR

Primary Symbol: LADX

Healthcare Biotechnology

LadRx Corp is a biopharmaceutical research and development company specializing in oncology. The Company focuses on the discovery, research and clinical development of anti-cancer drug candidates that employ technologies that target chemotherapeutic drugs to solid tumors and reduce off-target toxicities. The Company’s linker activated drug release (LADR) technology platform consists of an organic backbone that is attached to a chemo toxic agent. The LADR backbone is to first target and deliver the chemo toxic agent to the tumor environment, and then to release the chemo toxic agent within the tumor. The LADR Technology offers the opportunity for multiple pipeline drugs. The LADR development efforts are focused on two classes of ultra-high potency albumin-binding drugs. These LADR-based drugs, LADRs 7, 8, 9, and 10, combine the proprietary LADR backbone with derivatives of the auristatin and maytansinoid drug classes.

OTCQB:LADX - Post by User

LadRx Corp

Bullboard Posts

Comment by mart33on May 31, 2008 10:38am

734 Views

Post# 15130501

RE: Very Liquid

the capital that it rasied from the sale of its RX shares was acquired only a month ago, so the company really has not yet had an opportunity to put the cash into use. That is why i stress it is so important to see what the company will do with the cash, and how it will be put to good use.

As for the NASDAQ compliance issue, the stock is in the high 0.80's territory, so its too early to close the books on this one. Again, wheather the company can raise the SP above $1 will depend on any announcments with what the company is going to do with change in its pocket.

Bullboard Posts

Sona Nanotech reveals results from breast cancer study